Ads
related to: bortezomib and multiple myeloma treatment and prognosis
Search results
Results From The WOW.Com Content Network
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [3] It is generally used together with other medications. [3] It is given by injection. [4]
LCDD is associated with multiple myeloma in 39-59% of cases, with monoclonal gammopathy of renal significance in 39% of cases and may also be associated with lymphoplasmacytic lymphoma. [2] The median 5-year overall survival of LCDD patients is 70%. [2]
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
Bortezomib (Velcade) was approved in 2003. This was the first proteasome inhibitor approved for use in the U.S. Its boron atom binds the catalytic site of the 26S proteasome. [20] Carfilzomib (Kyprolis) was approved by the FDA for relapsed and refractory multiple myeloma in 2012 . [21]
The side effects of receiving bortezomib include chronic, distal, and symmetrical sensory peripheral neuropathy and neuropathic pain syndrome which may last for weeks, months, or years after treatment completion. [citation needed] 6) Immunomodulatory drugs, mainly thalidomide, are used to treat multiple myeloma. [3]
Bortezomib can also be given before and after an autologous stem cell transplant (ASCT) with high dose of the chemotherapy medication mephalan given before ASCT to eradicate the monoclonal gammopathy prior to transplant and prevent recurrence. [1] Alternative treatment options include immunomodulatory drugs such as thalidomide or lenalidomide. [1]
Ads
related to: bortezomib and multiple myeloma treatment and prognosis